Physician profile
Nelson M Fuentebella
NPI 1295075760
$12,079.45
in general payments reported to CMS, 2019-2025
39 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,432 · 2022: $2,392 · 2023: $3,902 · 2024: $2,681 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,842 · Travel and Lodging: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,841.51 |
| Travel and Lodging | $414.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $2,065.23 | 2023-2025 | Prospera, Biotronik |
| Abbvie INC. | $1,947.94 | 2021-2025 | |
| Relievant Medsystems, INC. | $1,114.62 | 2022-2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $776.86 | 2021-2024 | Relistor |
| Collegium Pharmaceutical, INC. | $657.15 | 2021-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $498.26 | 2021-2023 | Proclaim |
| Ibsa Pharma INC. | $481.26 | 2021-2025 | Tirosint, Tirosint, Licart |
| Medtronic, INC. | $449.32 | 2022-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Synchromedii |
| Painteq LLC | $413.79 | 2022-2023 | Painteq |
| Lundbeck LLC | $410.24 | 2021-2025 | Vyepti |
| Spr Therapeutics, INC | $360.13 | 2023-2025 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $277.15 | 2024-2025 | |
| Saluda Medical Americas, INC. | $244.80 | 2023-2025 | Evoke Scs, Evoke |
| Amgen INC. | $231.45 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $217.80 | 2021-2023 | Ztlido |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $210.22 | 2022-2023 | Senza |
| Almatica Pharma LLC | $199.16 | 2021-2023 | Gralise |
| Azurity Pharmaceuticals, INC. | $176.14 | 2023-2025 | Horizant, Horizant |
| Arbor Pharmaceuticals, INC. | $153.67 | 2021 | |
| Lilly USA, LLC | $121.10 | 2022-2023 | Reyvow, Emgality |
| Biohaven Pharmaceuticals, INC. | $114.20 | 2021 | |
| Biodelivery Sciences International, INC. | $111.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $98.67 | 2021-2022 | |
| West Therapeutics Development, LLC | $83.03 | 2021 | |
| Pfizer INC. | $73.93 | 2024-2025 | |
| Grt US Holding, INC. | $61.20 | 2021 | |
| Nalu Medical, INC. | $58.27 | 2023-2025 | Nalu Neurostimulation System |
| Virtus Pharmaceuticals LLC | $52.57 | 2025 | Levorphanol Tartrate |
| Boston Scientific Corporation | $50.61 | 2021-2025 | General - Pain Management |
| Tersera Therapeutics LLC | $49.11 | 2025 | Prialt |
| Stryker Corporation | $47.22 | 2021 | |
| Radius Health, INC. | $45.31 | 2022 | |
| Averitas Pharma INC. | $41.37 | 2023 | Qutenza |
| Foundation Fusion Solutions, LLC | $38.58 | 2024 | |
| Fidia Pharma USA INC. | $35.94 | 2024-2025 | Hymovis, Hyalgan, Triluron |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.09 | 2022 | |
| Spinal Simplicity, LLC | $31.84 | 2025 | Ha Minuteman G3-R |
| Tonix Medicines, INC. | $29.94 | 2025 | Tonmya |
| Redhill Biopharma INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Fuentebella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.